Association between Elevated Pleural Interleukin-33 Levels and Tuberculous Pleurisy

Koung-Sun Lee, M.D. 1,* Hak-Ryul Kim, M.D. 2,* Seongae Kwak, Ph.D. 3, Keum-Ha Choi, M.D. 3, Ji-Hyun Cho, M.D. 1, Young-Jin Lee, M.D. 1, Mi-Kyung Lee, M.D. 4,7, Jea-Hoon Lee, M.D. 5,7, Seok-Don Park, M.D. 6,7, and Do-Sim Park, M.D. 1,7,8

Departments of Laboratory Medicine 1, Internal Medicine 2, Pathology 3, Thoracic Surgery 4, Otorhinolaryngology-Head and Neck Surgery 5, Dermatology 6, Institute of Wonkwang Clinical Medicine & Genome Research Center for Immune Disorder 7, and Institute of Wonkwang Medical Science & Center for Metabolic Function Regulation 8, Wonkwang University School of Medicine, Iksan, Korea

Background: Interferon-γ (IFN-γ) plays a crucial role in Mycobacterium tuberculosis induced pleural responses. Interleukin (IL)-33 up-regulates the production of IFN-γ. We aimed to identify whether an association between pleural IL-33 levels and tuberculous pleurisy exists and determine its diagnostic value.

Methods: Pleural IL-33, ST2 (a receptor of IL-33), adenosine deaminase (ADA), and IFN-γ, as well as serum IL-33 and ST2 were measured in 220 patients with pleural effusions (PEs). Patients with malignant (MPEs), parapneumonic (PPEs), tuberculous (TPEs), and cardiogenic (CPEs) pleural effusions were included.

Results: Pleural and serum IL-33 levels were highest or tended to be higher in patients with TPEs than in those with other types of PEs. The median pleural fluid-to-serum IL-33 ratio was higher in TPE cases (≥ 0.91) than in other PE cases (≤ 0.56). Pleural IL-33 levels correlated with those of pleural ADA and IFN-γ. However, the diagnostic accuracies of pleural IL-33 (0.74) and pleural fluid-to-serum IL-33 ratio (0.75) were lower than that of ADA (0.95) or IFN-γ (0.97). Pleural ST2 levels in patients with MPEs were higher than in patients with TPEs. Serum ST2 levels did not differ among the groups.

Conclusions: We identified an association between elevated pleural IL-33 levels and tuberculous pleurisy. However, we recommend conventional pleural markers (ADA or IFN-γ) as diagnostic markers of TPE.

Key Words: Interleukin-33, ST2, Tuberculosis, Pleural effusion

INTRODUCTION

Tuberculosis (TB) is the second most important cause of death from infectious disease in the world [1]. Tuberculous pleurisy is one of the most common forms of extrapulmonary TB and may develop as a complication of pulmonary tuberculosis [2, 3]. Interferon-γ (IFN-γ), a Th1 cytokine produced predominantly by natural killer (NK) cells, natural killer T (NKT) cells, and Th1 cells [4-7], plays a pivotal role in pleural granuloma formation and protection against Mycobacterium tuberculosis (M. tuberculosis) [4-11].

Interleukin (IL)-33, an IL-1 family cytokine, is expressed in lung tissue. IL-33 displays pro-Th2 functions and is involved in allergic inflammation and asthma [12-15]. Recent studies found that IL-33 expression is induced by IFN-γ or tumor necrosis factor (TNF) [15-17], which are locally increased in the pleural space of patients with tuberculous pleural effusion (TPE) [18-20]. Conversely, additional studies demonstrated enhanced IFN-γ or TNF production by IL-33 and that the pro-Th1 functions of IL-33 are dependent upon the presence of IL-12 [13, 21-23]. IL-12 is a key player in host defense against M. tuberculosis and a crucial inducer of IFN-γ production [11, 24], which is remarkably ele-
Elevated IL-33 in tuberculous pleural effusion

ST2, a soluble IL-33 receptor, is expressed on Th2 cells and exerts Th2 effector functions upon IL-33 stimulation [12]. In addition, elevated levels of soluble ST2 are found in malignant pleural effusions (MPEs), which have a depressed Th1-mediated immune response [26, 27].

To date, there have been no studies on pleural IL-33 levels in human disease. We aimed to identify: 1) pleural IL-33 levels, their association with circulatory levels, and pleural IL-33 soluble receptor levels in patients with TPE; 2) the associations between pleural IL-33 and the conventional TPE markers, IFN-γ and adenosine deaminase (ADA) [8, 19, 28-30]; and 3) the diagnostic usefulness of IL-33 and its soluble receptor levels for the detection of tuberculous pleurisy.

**METHODS**

1. Study design and population

This study was a cross-sectional, case-control study. The study protocol was approved by the Institutional Review Board for Human Studies at the Clinical Research Center of Wonkwang University Hospital. All recruited subjects provided written informed consent.

A total of 537 consecutive patients with pleural effusions (PEs) were prospectively recruited upon admission to the Departments of Emergency, Internal Medicine, and Thoracic Surgery at Wonkwang University Hospital between January 2008 and November 2011. Of these, 317 subjects were excluded because the cause of PE did not definitely meet our diagnostic criteria or paired samples of pleural fluid and serum were not obtainable. Finally, 220 patients were enrolled into the study and all patients (N=220) had sufficient sample-volumes for duplicate pleural and serum IL-33 testing (Table 1). Pleural and serum ST2 were analyzed in 135 cases. We did not measure pleural and serum ST2 levels in 85 cases because sample volumes from these cases were insufficient. Pleural levels of ADA, IFN-γ, lactate dehydrogenase (LDH), total protein, and total lymphocytes were measured in all patients (Table 2).

2. Sample collection and quantification

Blood and/or pleural fluid samples were collected within 24 hr of admission or on a symptomatic day before treatment. Blood and/or pleural fluid were collected in plain tubes and centrifuged (1,200×g for 10 min) within 60 min of collection. The serum and pleural sample supernatants were stored at -75°C until IL-33, ST2, and IFN-γ analyses. Stability of IL-33 with repeated freezing-thawing was ensured for up to 10 freeze-thaw cycles. The change in IL-33 levels after 10 freeze-thaw cycles was less than 10% of the estimated pre-freeze concentration (data not shown).

IL-33 and ST2 levels were measured using commercial ELISA kits (R&D Systems, Minneapolis, MN, USA). IFN-γ levels were also measured with a commercially available ELISA kit (Cellestis, Carnegie, Australia). Measurements of IL-33, ST2, and IFN-γ

---

**Table 1. Characteristics of study subjects**

| Diagnosis                        | Enrolled subjects (N=220) | Presence of cancer cells | Age*, year mean + SD | Male sex† (N=140, 64%) | Tested subjects (N=220) |
|----------------------------------|---------------------------|--------------------------|----------------------|-------------------------|-------------------------|
|                                  | N                         | N (%)                    | IL-33 (N=220)        | ST2 (N=135)             | IL-33 (N=220) ST2 (N=135) |
| Malignancy with MPE              | 84                        | 51 (61)                  | 69 ±14 (1)           | 54 (64)                 | 84 63                   |
| Primary lung cancer              | 74                        | 47 (64)                  | 68 ±14               | 48 (65)                 | 74 60                   |
| Adenocarcinoma                   | 51                        | 39 (76)                  | 65 ±15               | 29 (57)                 | 51 38                   |
| Squamous cell carcinoma          | 7                         | 2 (29)                   | 77 ±12               | 7 (100)                 | 7 7                     |
| Small cell carcinoma             | 6                         | 4 (67)                   | 79 ±6                | 4 (67)                  | 6 6                     |
| Other carcinoma                  | 10                        | 2 (20)                   | 71 ±13               | 8 (80)                  | 10 9                    |
| Metastatic cancer                | 10                        | 4 (40)                   | 72 ±14               | 6 (60)                  | 10 3                    |
| Pneumonia with PPE               | 54                        | 0 (0)                    | 66 ±14 (1)           | 36 (67)                 | 54 32                   |
| Tuberculosis with TPE            | 60                        | 0 (0)                    | 55 ±23 (2)           | 40 (67)                 | 60 40                   |
| Heart failure with CPE           | 22                        | 0 (0)                    | 71 ±12 (1)           | 10 (45)                 | 22 0                    |

*Mean ages of the groups increased significantly (P<0.05) according to the decreasing values in parentheses, and equal numbers in parentheses indicate that there was no significant difference between the respective groups; †Sex ratios were not significantly (P>0.05) different among the 4 groups; ‡Pleural and serum ST2 were analyzed in 135 cases. Of the 220 patients, 85 cases (heart failure 22, malignancy 21, pneumonia 22, tuberculosis 20) were unable to be tested for pleural and serum ST2 because of insufficient sample volume.

Abbreviations: MPE, malignant pleural effusion; PPE, parapneumonic pleural effusion; TPE, tuberculous pleural effusion; CPE, cardiogenic pleural effusion.
were performed in duplicate and the results were averaged. The limits of detection for IL-33, ST2, and IFN-γ were 10 pg/mL, 6 pg/mL, and 0.06 IU/mL, respectively. Values of 10 (IL-33), 6 (ST2) or 0.06 (IFN-γ) were assigned to results that were below a particular assay’s limit of detection. The maximum linear responses of IL-33, ST2, and IFN-γ were 1,500 pg/mL, 2,000 pg/mL, and 40 IU/mL, respectively. Samples with values greater than the maximum linear response were diluted 10-fold and reanalyzed. If the 10-fold diluted sample levels were higher than the linear range, 100-fold dilutions were performed. The IL-33 test indicated no significant cross-reactivity with or interference by 50 ng/mL of the following cytokines (ST2, IL-1α, IL-1β, IL-2, IL-6, IL-12, IL-18, IFN-γ, and TNF-α). None of the 3 ELISA kits were validated by the manufacturer for the accuracy of pleural fluid analyses. In the current study, we analyzed pleural fluids using each ELISA kit as an experimental pilot research. Dilution assessment of each sample by using 4 different concentrations of each patient pleural fluid sample indicated that signal level depended on sample dilution levels (90-110% of expected values) for each cytokine. Spike and recovery assessment of pleural fluid sample demonstrated acceptable performances (90-110% of recovery rates) for each cytokine. Levels of ADA (Diazyme Laboratories, San Diego, CA, USA), LDH, and total protein were analyzed by routine clinical laboratory test protocols using an automated chemical analyzer (Modular P800; Roche Diagnostics GmbH, Mannheim, Germany).

### Table 2. Pleural fluid and serum characteristics of the 220 patients with pleural effusions

|                    | N        | TPE                  | MPE                  | PPE                  | CPE                  | P value* |
|--------------------|----------|----------------------|----------------------|----------------------|----------------------|----------|
| Pleural fluid      |          |                      |                      |                      |                      |          |
| IL-33 (pg/mL)      | 220      | 31 (10-3,058)1,1,5   | 10 (10-350)1         | 10 (10-604)1         | 10 (10-66)1          | <0.001   |
| ST2 (pg/mL)        | 135      | 343 (55-4,254)1      | 519 (54-7,932)1      | 426 (53-3,293)       | -                    | 0.04     |
| ADA (IU/L)         | 220      | 51 (8-88)1,1,5       | 10 (3-38)1,1,5       | 14 (3-132)1,1,5      | 3 (2-6)1,1,5         | <0.001   |
| IFN-γ (IU/mL)      | 220      | 64 (0.06-497)1,1,5   | 0.06 (0.06-0.89)1,1,5| 0.06 (0.06-0.62)1,1,5| 0.06 (0.06-0.40)1,1,5| <0.001   |
| LDH (IU/L)         | 220      | 782 (334-2,421)1,1,5 | 570 (156-3,223)1,1,5 | 498 (131-8,240)1,1,5 | 144 (102-199)1,1,5   | <0.001   |
| Total protein (g/L)| 220      | 54 (28-63)1,1,5      | 45 (23-65)1,1,5      | 43 (27-67)1,1,5      | 23 (9-29)1,1,5       | <0.001   |
| Lymphocytes (%)    | 220      | 81 (33-95)1,1,5      | 57 (3-97)1,1,5       | 10 (1-69)1,1,5       | 68 (55-86)1,1,5      | <0.001   |
| Serum              |          |                      |                      |                      |                      |          |
| IL-33 (pg/mL)      | 220      | 26 (10-6,691)1,5     | 16 (10-837)1         | 23 (10-702)          | 10 (10-104)1         | 0.03     |
| ST2 (pg/mL)        | 135      | 328 (39-4,351)       | 440 (11-5,640)       | 534 (51-5,119)       | -                    | 0.34     |
| P/S IL-33 ratio    |          |                      |                      |                      |                      |          |
| Total cases§       | 220      | 0.91 (0.00-3.90)1,1,5| 0.25 (0.00-4.90)1,1,5| 0.30 (0.00-1.65)1,1,5| 0.00 (0.00-0.93)1,1,5| <0.001   |
| PE or Serum > 10 pg/mL** | 146 | 1.06 (0.18-3.90)1,1,5| 0.56 (0.08-4.90)1,1,5| 0.43 (0.04-1.65)1,1,5| 0.43 (0.11-0.93)1,1,5| <0.001   |
| PE or Serum > 15 pg/mL†† | 132 | 1.02 (0.18-3.90)1,1,5| 0.54 (0.08-4.90)1,1,5| 0.41 (0.04-1.65)1,1,5| 0.40 (0.11-0.93)1,1,5| <0.001   |

Values are expressed as medians (full range).

*By Kruskal-Wallis test; †P < 0.05, vs. MPE; †P < 0.05 vs. PPE; ††P < 0.05 vs. TPE; †A value of zero was assigned to pleural fluid-to-serum (P/S) ratios of cases with both pleural and serum IL-33 levels ≤ 10 pg/mL (detection limit); **The cases have higher IL-33 levels in either pleural fluid or serum or in both specimens than 1.5 times the detection limit; §The cases have higher IL-33 levels in either pleural fluid or serum or in both specimens than 1.5 times the detection limit.

Abbreviations: TPE, tuberculous pleural effusion; MPE, malignant pleural effusion; PPE, parapneumonic pleural effusion; CPE, cardiogenic pleural effusion; ADA, adenosine deaminase; IFN-γ, interferon gamma; LDH, lactate dehydrogenase.
urine as a cause of transudative PE with the exclusion of any other cause of PE. All exudates were defined as described by Light et al [31].

4. Statistical analyses
Gender ratios and proportions were compared using chi-square tests. Mean ages were compared using a one-way ANOVA followed by Tukey’s Honestly Significant Difference (HSD) post-hoc tests. The median levels of sera and pleural fluid markers were compared using nonparametric tests, because the concentrations were not normally distributed. Differences between more than 2 groups were determined using Kruskal-Wallis tests, with subsequent Conover post-hoc tests if the differences were significant. Spearman correlations were used to determine the relationships between the levels of pleural IL-33 and levels of pleural ADA or IFN-γ.

The diagnostic accuracies of pleural markers for discriminating the etiology of PEs were determined through analyses of ROC curves. Statistical differences were analyzed using the DeLong method. Data were analyzed using MedCalc version 11.5 (MedCalc Software, Mariakerke, Belgium) and SPSS version 15 (SPSS Inc., Chicago, IL, USA). P values<0.05 were considered statistically significant.

RESULTS

1. Demographic characteristics of the study subjects and basic characteristics of pleural fluid samples
The demographic characteristics of the study subjects are presented in Table 1. The mean ages of subjects in the malignancy, pneumonia, and heart failure groups were higher than that of the tuberculosis group. The groups did not significantly differ with regard to subject gender. The basic characteristics of the pleural fluid samples are recorded in Table 2.

2. Levels of IL-33 in PEs and serum
The median level of pleural IL-33 was higher in patients with TPEs (31 pg/mL) than in patients with other types of PEs (MPE 10 pg/mL, P<0.001; PPE 10 pg/mL, P<0.001; and CPE 10 pg/mL, P<0.001) (Table 2). The median levels of pleural IL-33 were not significantly different among the patients with MPEs, PPEs, and CPEs. The median level of serum IL-33 was significantly higher in patients with TPEs (26 pg/mL) than in patients with MPEs (16 pg/mL, P=0.03) or CPEs (10 pg/mL, P=0.01), and tended to be greater in patients with TPEs compared to levels in patients with PPEs (23 pg/mL, P=0.42) (Table 2).

3. Levels of ST2 in PEs and serum
The median level of pleural ST2 was significantly higher in patients with MPEs (519 pg/mL) than in patients with TPEs (343 pg/mL, P=0.01), and tended to be higher in patients with MPEs than in patients with PPEs (426 pg/mL, P=0.30) (Table 2). There were no significant differences in median levels of serum ST2 among the MPE, PPE, and TPE groups (P=0.34) (Table 2).

4. Relationship between pleural/serum (P/S) IL-33 ratio and etiologies of PE
The relationship between pleural/serum (P/S) IL-33 ratio and etiologies of PE are shown in Table 2. The median P/S IL-33 ratio was significantly higher in patients with TPEs (≥0.91) than in patients with MPEs, PPEs, or CPEs (≤0.56, P<0.001). This result held true for all cases and in cases with IL-33 pleural fluid or serum levels above the detection limit (10 pg/mL) or 1.5 times the detection limit (15 pg/mL). The median P/S ratios were not different or were only marginally different among the patients with MPEs, PPEs, and CPEs.

5. Correlations between levels of pleural IL-33 and pleural ADA or IFN-γ levels
Correlations between levels of pleural IL-33 and pleural ADA or IFN-γ levels in patients with PEs were analyzed using Spearman rank correlations (Fig. 1). There were statistically significant positive correlations between IL-33 levels and ADA levels (r=0.37, P<0.001) and between IL-33 levels and IFN-γ levels (r=0.29, P<0.001) in the pleural fluid samples of the PE patients.

6. Diagnostic values of IL-33 and ST2 in PEs
In ROC curve analysis (Fig. 2), the diagnostic accuracies of pleural IL-33 (0.74) and P/S IL-33 ratio (0.75) for discrimination between patients with TPEs and patients with non-TPEs were fairly good. However, they were lower than that of pleural ADA (0.95, P<0.001) or IFN-γ (0.97, P<0.001). The diagnostic sensitivity and specificity of pleural IL-33 were lower than those of pleural ADA or IFN-γ. The area under the ROC curve (AUC) of pleural ST2 (0.61)

DISCUSSION

IL-33 promotes Th2 cytokine production and represses induction of IFN-γ in Th1-polarized cells [12]. On the other hand, it directly interacts with invariant NKT (iNKT) cells to induce IFN-γ production [13]. The accumulated evidence and conflicting hypotheses for IL-33 involvement in inflammatory responses and
We found significantly higher levels of pleural IL-33 in TPEs than in all other types of PEs. Moreover, P/S IL-33 ratios were higher in patients with TPEs than in patients with other types of PEs [18-20]. These data also agree with the fact that the concentration ratio (pleural fluid to circulatory blood) of tuberculous pleurisy-involved cytokine is higher in patients with TPE [20]. Further, our results demonstrated significant correlations between pleural IL-33 levels and the pleural levels of conventional TPE markers, IFN-γ and ADA [18, 19, 28-30].

Taken together, these findings indicate that IL-33 is more specifically associated with the pathophysiology of TPE than with other types of PE. Our data are consistent with the observations that IL-33 amplifies Th1 functions and induces a preferential increase in IFN-γ rather than Th2 cytokines production in vivo [13, 23]. Although we did not define the mechanism of IL-33 contribution to TPE pathogenesis, the significant relationship between IL-33 and tuberculosis pleurisy observed in this study could be explained by the following hypotheses: First, IL-33 may render relatively specific immunomodulatory effects, in regard to induced cytokines and responding cells caused by tuberculosis rather than by other etiologies. Indeed, recognition of tuberculosis-infected macrophages by iNKT cells is followed by IFN-γ production [5]. In addition, IFN-γ is not only an upstream regulator of Th1 responses, but also plays a critical role in the activation of immune cells and the induction of protective immune responses against tuberculosis. Therefore, the significant correlation between pleural IL-33 levels and IFN-γ levels observed in this study could be attributed to the preferential induction of Th1 responses in patients with TPE.
of IL-33 [15-17] but also a downstream product of IL-33 signal-
ing [13, 21-23]. Consequently, IFN-γ and IL-33 may form a cou-
pled positive feedback loop in tuberculous pleurisy [13, 15-17,
22, 23]. IL-33 is more strongly induced in activated macroph-
ages, but not in resting macrophages [12], and pleural granulo-
matous lesions, an organized collection of “activated” macro-
phages, are far more frequently seen in tuberculous pleurisy
than in other types of pleurisy. In addition, variant cells in lung
parenchyma and pleural cells may induce IL-33 via IFN-γ and
TNF. Second, the “alarmin” effect [35] may be induced to alert
the immune system of a local threat by destructed or necrotic
cells during tuberculosis infection.

There was a significant elevation of IL-33 levels in TPE in cur-
rent study, and reported cellular experiments presented patho-
physiologic association between IL-33 and IFN-γ [13, 15-17,
22, 23]. Nevertheless, our data indicate that pleural IL-33 and the P/
S IL-33 ratio were not efficient diagnostic markers for detection
of TPE, even though our results for pleural IFN-γ and ADA were
similar to those of previous studies [28-30].

Pleural ST2 levels in MPEs were significantly higher than in
TPEs. Thus, our results confirmed previous observations of ST2
in MPE [26]. However, the poor diagnostic accuracy of pleural
ST2 abrogates its utility as a marker for differential diagnosis of
PE.

Our study has several limitations. First, we presented limited
data for a single point cross-sectional test, did not analyze serial
IL-33 levels and did not measure Th2 and Th1 cytokines other
than IFN-γ in PEs. Therefore, we could neither confirm that a
decrease of IL-33 preceded recovery from tuberculous pleurisy,
nor define the heterogeneous effects of IL-33 during disease
progression. A shift from a pro-Th 1 response to a pro-Th 2 re-
ponse depends on changes in pleural micro-environmental condi-
tions. For instance, in the early stages of tuberculous pleu-
risy, naive macrophages may become activated macrophages
(M1) by IL-33, and levels of which may correlate with Th1 cyto-
kine levels in TPE for the increased Th1 cell-attracting M1 mac-
rophages. In the advanced stages of tuberculous pleurisy, the
M1 phenotype macrophages may subsequently change to M2
phenotype cells [36]. Thereafter, IL-33 may no longer form a
positive feedback system with Th1 cytokines. In the end stage
of immune activation that is close to the recovery phase of tu-
berculous pleurisy, the decrease of Th1 cytokines may not be
followed by a decrease in IL-33. During this stage, IL-33 may be
positively correlated with Th2 cytokines instead of Th1 cytokines.
Second, our study did not examine the cellular levels of IL-33 in
PEs, which is required for a more precise identification of the
immune response and the cellular source of IL-33 in TPEs.

As a pilot study for IL-33 in pleural disease, we focused on
pleural IL-33 levels in PEs and observed higher pleural IL-33
levels and P/S IL-33 ratios in tuberculous pleurisy and correla-
tions between pleural IL-33 and conventional TPE markers. The
results of our study reflect the involvement of IL-33 in the patho-
genesis of tuberculous pleurisy. However, we strongly recom-
mand the use of pleural ADA or IFN-γ, rather than pleural IL-33,
for detection of TPE, because of the proven diagnostic power of
these conventional markers.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were re-
ported.

Acknowledgement

This research was supported by Wonkwang University in 2011.

REFERENCES

1. Caramori G, Lasagna L, Casalini AG, Adcock IM, Casolari P, Contolli M,
et al. Immune response to Mycobacterium tuberculosis infection in the parietal pleura of patients with tuberculous pleurisy. PLoS One 2011;6:
e22637.
2. Baumann MH, Nolan R, Petritini M, Lee YC, Light RW, Schneider E. Ple-
ural tuberculosis in the United States: incidence and drug resistance. Chest
2007;131:1125-32.
3. Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988;138:184-
234.
4. Sneller MC. Granuloma formation, implications for the pathogenesis of vasculitis. Cleve Clin J Med 2002;69(S2):S40-3.
5. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate in-
viant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS
Pathog 2008;4:e1000239.
6. Schierloh P, Yokobori N, Aleman M, Landoni V, Gelfner L, Musella RM,
et al. Mycobacterium tuberculosis-induced gamma interferon produc-
tion by natural killer cells requires cross talk with antigen-presenting
cells involving Toll-like receptors 2 and 4 and the mannose receptor in
tuberculous pleurisy. Infect Immun 2007;75:6325-37.
7. Feng CG, Kaviratne M, Rothfuchs AG, Cheever A, Hiery S, Young HA,
et al. NK cell-derived IFN-gamma differentially regulates innate resis-
tance and neutrophil response in T cell-deficient hosts infected with
Mycobacterium tuberculosis. J Immunol 2006;177:7086-93.
8. Orme IM and Cooper AM. Cytokine/chemokine cascades in immunity
to tuberculosis. Immunol Today 1999;20:307-12.
9. Pasquinelli V, Townsend JC, Jurado JO, Alvarez IB, Quiroga MF, Barnes
PF, et al. IFN-gamma production during active tuberculosis is regulated
by mechanisms that involve IL-17, SLAM, and CREB. J Infect Dis 2009;
199:661-5.
Elevated IL-33 in tuberculous pleural effusion

10. Asano M, Nakane A, Minagawa T. Endogenous gamma interferon is essential in granuloma formation induced by glycolipid-containing mycoelic acid in mice. Infect Immun 1993;61:2872-8.

11. van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev 2002;15:294-309.

12. Schmitz O, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. J Immunol 2005;23:479-90.

13. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009;39:1046-55.

14. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010;40:200-8.

15. Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009;183:5094-103.

16. Masamune A, Watanabe T, Kikuta K, Satoh K, Kanno A, Shimosegawa T. Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2010;299:G821-32.

17. Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun 2009;384:105-9.

18. Wong CF, Yew WW, Leung SK, Chan CY, Hui M, Au-Yeung C, et al. Assay of pleural fluid interleukin-6, tumour necrosis factor-alpha and interferon-gamma in the diagnosis and outcome correlation of tuberculous effusion. Respir Med 2003;97:1289-95.

19. Orphanidou D, Giga M, Rasidakis A, Dimakou K, Toumbis M, Latsi P, et al. Tumour necrosis factor, interleukin-1 and adenosine deaminase in tuberculous pleural effusion. Respir Med 2003;97:1289-95.

20. Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazumder A, Modlin RL. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol 1990;145:149-54.

21. Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, Synguelakis M, von Aulock S, Sallenave JM, et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 2009;183:1446-55.

22. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008;105:10913-8.

23. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both TH1- and TH2-type responses through its activity on human basophils, allergen-reactive TH2 cells, iNKT and NK cells. Int Immunol 2008;20:1019-30.

24. Cooper AM, Solache A, Khadera SA. Interleukin-12 and tuberculosis: an old story revisited. Curr Opin Immunol 2007;19:441-7.

25. Valdés L, San José E, Alvarez Dobaño JM, Golpe A, Valle JM, Penela P, et al. Diagnostic value of interleukin-12 p40 in tuberculous pleural effusions. Eur Respir J 2009;33:816-20.

26. Oshikawa K, Yanagisawa K, Ohno S, Tominaga S, Sugiyama Y. Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am J Respir Crit Care Med 2002;165:1005-9.

27. Okamoto M, Hasegawa Y, Hara T, Hashimoto N, Imaizumi K, Shimokata K, et al. T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. Chest 2005;128:4030-5.

28. Axe K, Hiraki A, Murakami T, Eda R, Maeda T, Sugi K, et al. Diagnostic significance of interferon-gamma in tuberculous pleural effusions. Chest 2003;123:740-4.

29. Greco S, Girardi E, Masciangelo R, Capocetta GB, Saltini C. Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a meta-analysis. Int J Tuberc Lung Dis 2003;7:777-86.

30. Boonyagars L and Kiertiburanakul S. Use of adenosine deaminase for the diagnosis of tuberculosis: a review. J Infect Dis Antimicrob Agents 2010;27:111-8.

31. Light RW, Macgregor MI, Luchsininger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-13.

32. Oboki K, Ohno T, Kawaiwa N, Saito H, Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010;59:143-60.

33. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm 2011;8:22.

34. Chen YM, Yang WK, Ting CC, Tsai WY, Yang DM, Whang-Peng J, et al. Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients. Chest 1997;112:960-4.

35. Mousson C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’. PLoS One 2008;3:e3331.

36. Joshi AD, Oak SR, Hartigan AJ, Finn WG, Kunkel SL, Duffy KE, et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol 2010;11:52.